Tacrolimus-eluting stent with biodegradable polymer is more effective than sirolimus- and everolimus-eluting stent in rabbit iliac artery restenosis model

[1]  J. Nah,et al.  Blood-compatible and biodegradable polymer-coated drug-eluting stent , 2015, Macromolecular Research.

[2]  Jong Chun Park,et al.  Mechanical behavior and in vivo properties of newly designed bare metal stent for enhanced flexibility , 2015 .

[3]  M. Jeong,et al.  Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model , 2013, Chonnam medical journal.

[4]  Y. Hayashi,et al.  Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) , 2012, Circulation.

[5]  M. Jeong,et al.  Nitrogen-doped TiO2 films as drug-binding matrices for the preparation of drug-eluting stents , 2011 .

[6]  G. Unger,et al.  Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points , 2010, Clinical Research in Cardiology.

[7]  R. Virmani,et al.  Drug-Eluting Stents in Preclinical Studies: Updated Consensus Recommendations for Preclinical Evaluation , 2008, Circulation. Cardiovascular interventions.

[8]  P. Fitzgerald,et al.  Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.

[9]  P. Serruys,et al.  Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same? , 2007, Circulation.

[10]  I. Rozenberg,et al.  Effects of Tacrolimus or Sirolimus on Proliferation of Vascular Smooth Muscle and Endothelial Cells , 2006, Journal of cardiovascular pharmacology.

[11]  B. Rensing,et al.  Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions , 2006, Circulation.

[12]  A. Webster,et al.  Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data , 2005, BMJ : British Medical Journal.

[13]  E. Graziani,et al.  Production of Novel Rapamycin Analogs by Precursor-Directed Biosynthesis , 2005, Applied and Environmental Microbiology.

[14]  P. Lemos,et al.  Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry , 2004, Heart.

[15]  P. Serruys,et al.  Evaluation of coronary remodeling after sirolimus-eluting stent implantation by serial three-dimensional intravascular ultrasound. , 2003, The American journal of cardiology.

[16]  D. Baim,et al.  Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. , 2002, Journal of the American College of Cardiology.

[17]  Richard R. Heuser,et al.  Randomized Trial of 90Sr/90Y β-Radiation Versus Placebo Control for Treatment of In-Stent Restenosis , 2002 .

[18]  P. Teirstein,et al.  Five-Year Clinical Follow-Up After Intracoronary Radiation: Results of a Randomized Clinical Trial , 2002, Circulation.

[19]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[20]  A. Yeung,et al.  Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial , 2002, The Lancet.

[21]  P. Teirstein,et al.  Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. , 2001, The New England journal of medicine.

[22]  Jeffrey J. Popma,et al.  Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001, Circulation.

[23]  P. Serruys,et al.  Radioactive Stents Delay but Do Not Prevent In-Stent Neointimal Hyperplasia , 2001, Circulation.

[24]  P. Fitzgerald,et al.  Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. , 2000, Circulation.

[25]  M. Leon,et al.  Intracoronary β-Radiation Therapy Inhibits Recurrence of In-Stent Restenosis , 2000 .

[26]  S. Sehgal.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. , 1998, Clinical biochemistry.

[27]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[28]  R. Califf,et al.  Restenosis after coronary angioplasty: an overview. , 1991, Journal of the American College of Cardiology.

[29]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .

[30]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[31]  M. Monaco,et al.  Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells. , 2012, American journal of physiology. Heart and circulatory physiology.

[32]  C. Tei,et al.  Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model. , 2010, Atherosclerosis.